The Heart Transplant Rejection drugs in development market research report provides comprehensive information on the therapeutics under development for Heart Transplant Rejection, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Heart Transplant Rejection. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Heart Transplant Rejection and features dormant and discontinued products.
GlobalData tracks five drugs in development for Heart Transplant Rejection by five companies/universities/institutes. The top development phase for Heart Transplant Rejection is preclinical with two drugs in that stage. The Heart Transplant Rejection pipeline has three drugs in development by companies and two by universities/ institutes. Some of the companies in the Heart Transplant Rejection pipeline products market are: Tonix Pharmaceuticals Holding, Johns Hopkins University and Bristol-Myers Squibb.
The key targets in the Heart Transplant Rejection pipeline products market include Janus Kinase, Acid Sensing Ion Channel 1, and CD40 Ligand.
The key mechanisms of action in the Heart Transplant Rejection pipeline product include Janus Kinase Inhibitor with one drug in Preclinical. The Heart Transplant Rejection pipeline products include two routes of administration with the top ROA being Intravenous and five key molecule types in the Heart Transplant Rejection pipeline products market including Cell Therapy, and Monoclonal Antibody.
Heart Transplant Rejection overview
Heart transplantation is the therapy used to treat various heart diseases by replacing an injured or diseased heart with a healthy one. Risk factors associated with transplantation are bleeding, infection, clots, and cardiovascular disorders. Following a transplantation, the immune system may consider the transplanted heart as foreign and may work against it. Patients may hence develop complications and eventually reject the new organ. Immunosuppressive drugs are administered simultaneously that prevent the body from either identifying or attacking the foreign organ via various immune responses, thus blocking organ rejection and facilitating a successful transplant.
For a complete picture of Heart Transplant Rejection’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
